Pfizer CentreOne Header Pfizer CentreOne Header

X

Find the latest Drugs in Development and Pipeline Prospector News of GSK.

  • Webinars & Exhibitions

PharmaCompass
Send me more info on How To Grow My Bussiness Digitally?
GSK
unitedkingdom_new Flag
Country
Country
United Kingdom
Address
Address
980 Great West Road, Brentford, Middlesex TW8 9GS England
Telephone
Telephone
+44 (0)20 8047 5000
Linkedin
Linkedin
Twitter
Twitter

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Details:

Apretude (cabotegravir) long-acting for PrEP is an integrase strand transfer inhibitor (INSTI), which is indicated for the treatment of sexually acquired HIV-1 infection.


Lead Product(s): Cabotegravir

Therapeutic Area: Infections and Infectious Diseases Product Name: Apretude

Highest Development Status: ApprovedProduct Type: Small molecule

Recipient: GSK

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable September 19, 2023

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content
  • Development Update

Details:

Ojjaara (momelotinib) has a novel mechanism of action, with inhibitory ability along three key signalling pathways: Janus kinase (JAK) 1, JAK2, and activin A receptor, type I (ACVR1), which is approved for myelofibrosis and contributes to anaemia.


Lead Product(s): Momelotinib

Therapeutic Area: Oncology Product Name: Ojjaara

Highest Development Status: ApprovedProduct Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable September 15, 2023

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content
  • Development Update

Details:

GS-0387 (momelotinib) has a novel mechanism of action, with inhibitory ability along three key signalling pathways: Janus kinase (JAK) 1, JAK2, and activin A receptor, type I (ACVR1), which is investicated for myelofibrosis and contributes to anaemia.


Lead Product(s): Momelotinib

Therapeutic Area: Oncology Product Name: GS-0387

Highest Development Status: Phase IIIProduct Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable September 11, 2023

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content
  • Development Update

Details:

Nucala (mepolizumab) is the first-in-class monoclonal antibody to target IL-5. It is believed to work by preventing IL-5 from binding to its receptor on the surface of eosinophils, reducing blood eosinophils and maintaining them within normal levels.


Lead Product(s): Mepolizumab

Therapeutic Area: Otolaryngology (Ear, Nose, Throat) Product Name: Nucala

Highest Development Status: Phase IIIProduct Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable September 01, 2023

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content
  • Development Update

Details:

Shingrix (recombinant zoster vaccine – RZV) is a non-live, recombinant sub-unit vaccine indicated for the prevention of herpes zoster (HZ) in adults aged 50 and over.


Lead Product(s): Guaifenesin,Adjuvanted Recombinant Zoster Vaccine

Therapeutic Area: Infections and Infectious Diseases Product Name: Shingrix

Highest Development Status: Phase IVProduct Type: Vaccine

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable August 23, 2023

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content
  • Development Update

Details:

GSK101 (IDE705), a small molecule inhibitor of Pol Theta Helicase, in combination with niraparib, the GSK small molecule inhibitor of PARP for the treatment of patients having tumors with BRCA or other homologous recombination mutations.


Lead Product(s): IDE705,Niraparib Tosylate

Therapeutic Area: Oncology Product Name: GSK101

Highest Development Status: IND EnablingProduct Type: Small molecule

Recipient: Ideaya Biosciences

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable August 21, 2023

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content
  • Development Update

Details:

The monovalent candidate, CV0601, encodes the spike protein of the omicron BA.4-5 variant and is being developed in collaboration with GSK


Lead Product(s): CV0601

Therapeutic Area: Infections and Infectious Diseases Product Name: CV0601

Highest Development Status: Phase IIProduct Type: Vaccine

Recipient: CureVac

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable August 01, 2023

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content
  • Development Update

Details:

JEMPERLI (dostarlimab-gxly) is a programmed death receptor-1 (PD-1)-blocking antibody that binds to the PD-1 receptor and blocks its interaction with the PD-1 ligands PD-L1 and PD-L2.


Lead Product(s): Dostarlimab-gxly,Carboplatin,Paclitaxel

Therapeutic Area: Oncology Product Name: Jemperli

Highest Development Status: ApprovedProduct Type: Large molecule

Recipient: AnaptysBio

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable July 31, 2023

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

CAB LA (cabotegravir) long-acting for PrEP is an integrase strand transfer inhibitor (INSTI). INSTIs, like cabotegravir extended-release injectable suspension, inhibit HIV replication by preventing the viral DNA from integrating into the genetic material of human immune cells.


Lead Product(s): Cabotegravir

Therapeutic Area: Infections and Infectious Diseases Product Name: CAB LA

Highest Development Status: ApprovedProduct Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable July 24, 2023

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content
  • Deals

Details:

The collaboration aims to advance the discovery and development of Elsie’s innovative oligonucleotide discovery platform for finding novel oligonucleotides by combining GSK's extensive expertise in DNA encoded library technologies with Elsie's drug discovery platform.


Lead Product(s): Oligonucleotide Drug

Therapeutic Area: Technology Product Name: Undisclosed

Highest Development Status: Discovery PlatformProduct Type: Large molecule

Recipient: Elsie Biotechnologies

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Collaboration July 10, 2023

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty
Post Enquiry
POST ENQUIRY